Eiger BioPharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2023

EIGER BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36183		33-0971591
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Eiger BioPharmaceuticals, Inc.

2155 Park Blvd.

Palo Alto, California94306

(Address of principal executive offices, including zip code)

[phone]

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		EIGR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 15, 2023, Eiger BioPharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-voteswith respect to each matter. A more complete description of each matter is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2023.

Proposal 1-Election of Directors

Nominees		Final Voting Results
	For		Withheld		Broker Non-Votes
Jeffrey S. Glenn, M.D., Ph.D.		23,346,453		2,036,859		7,952,548
Evan Loh, M.D.		14,074,196		11,309,116		7,952,548
Amit K. Sachdev, J.D.		23,025,306		2,358,006		7,952,548

The Company's stockholders elected each of the three nominees for director to serve until the 2026 annual meeting of stockholders and until his respective successor is elected.

Proposal 2-Advisory Vote on Executive Compensation

		Final Voting Results
For		Against		Abstain		Broker Non-Votes
9,827,476		15,512,014		43,822		7,952,548

The Company's stockholders did not approve, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.

Proposal 3-Ratification of Selection of Independent Registered Public Accounting Firm

		Final Voting Results
For		Against		Abstain
33,163,930		165,047		6,883

The Company's stockholders ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

No other matters were submitted for stockholder action.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Eiger BioPharmaceuticals, Inc.
Dated: June 16, 2023
		By:		/s/ James Vollins
			James Vollins
			General Counsel, Chief Compliance Officer & Corporate Secretary at Eiger BioPharmaceuticals